FDA 483 - Bactolac Pharmaceutical, Inc. - February 07, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Bactolac Pharmaceutical, Inc. in Hauppauge, NY, revealed significant deficiencies in quality control and facility maintenance for dietary supplements. Observations included inadequate testing for finished product specifications and raw material identity, a lack of established contamination limits for components, and improper storage of rejected products. Additionally, the facility exhibited a severe pest infestation and unsanitary conditions, indicating a high risk of product adulteration and contamination.
ID · 478af956-5153-4db0-a53c-4b6fa00c1f95